To Score Big Pharma Support With Pfizer Deal

/Home/Biologics Delivery - Protein Synthesis/RNA - Protein Synthesis/RNAi - Protein Synthesis

Quark Becomes Latest RNAi Drug Developer To Score Big Pharma Support With Pfizer Deal
September 28, 2006
by Doug Macron
RNAi News
Under the deal, Pfizer has acquired an exclusive license to RTP-801, Quark?s proprietary gene target associated with numerous diseases, as well as the company?s investigational siRNA-based treatment for age-related macular degeneration.
NOTE: A paid subscription to RNAi News daily is required to read this article in its entirety online.